House Ear Institute

The United States of America, As Represented by the Secretary, Department of Health and Human Services

House Research Institute

David J Lim

Tomas Ganz

Paul Webster

Ali Andalibi

Haa-Yung Lee

Jian-Dong Li

John B Robbins

Xin-Xing Gu

Chao-Ming Tsai

Kiweon Cha

Johng S Rhim

Young-Myoung Chun

Derald E Brackmann

The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.

Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis

Disclosed herein is a composition and a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and/or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the bodies response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin, and defensins were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.

Disclosed herein is a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and/or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the bodies response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin and defensins, were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.

A conjugate vaccine for Nontypeable comprising lipooligosaccharide from which esterified fatty acids have been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of otitis media and respiratory infections in mammals.

Conjugate vaccine for nontypeable Haemophilus influenzae

Human middle ear epithelial cell lines permanently transformed by human papilloma viruses have been obtained. These cell lines are useful for the study of gene and protein expression in otitis media and the identification of chemical and biological agents that may be useful in the therapy of human otitis media and other diseases of the ear.

Immortalized human middle ear epithelial cell lines

A conjugate vaccine for Nontypeable,comprising lipooligosaccharide from which esterified fatty acids have been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of otitis media and respiratory infections in mammals.

Growing community of inventors

Pasadena, CA, United States of America

David J Lim